<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122892">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502761</url>
  </required_header>
  <id_info>
    <org_study_id>HS-11-00339</org_study_id>
    <nct_id>NCT01502761</nct_id>
  </id_info>
  <brief_title>Intra-arterial Magnesium Administration for Acute Stroke</brief_title>
  <official_title>Intra-arterial Magnesium Therapy: A Novel Platorm for Neuroprotectant Delivery in Acute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the second leading cause of death and the leading cause of adult disability
      worldwide. This investigation will address the safety and feasibility of directed,
      intra-arterial Magnesium measurement and therapy, through endovascular access, in acute
      stroke patients. The proposal represents the first study to directly quantify levels of a
      systemically administered neuroprotectant in the region of cerebral ischemia. It also
      establishes a novel endovascular platform for direct delivery of neuroprotective agents to
      ischemic cerebral tissue distal to an occlusive thrombus. This research seeks to improve
      patient care by establishing a novel delivery mechanism for the rescue of threatened brain
      parenchyma that can be administered rapidly following acute stroke. If successful, this
      selective distribution will allow delivery to &quot;at risk&quot; tissue in a rapid manner. Salvage of
      viable, but threatened, penumbral tissue could afford stroke patients an increased
      probability of favorable long term outcome. The investigators hypothesize that endovascular,
      intra-arterial, Magnesium administration will deliver high concentration of this
      neuroprotective agent to otherwise inaccessible cerebral territories, while limiting
      systemic concentrations. The proposed investigation will evaluate the safety and feasibility
      of this novel treatment technique
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnesium concentration in region of cerebral ischemia</measure>
    <time_frame>following fist pass of the clot retriever (average 1 minute after Mg administration)</time_frame>
    <description>Systemic Magnesium levels will be obtained through the femoral sheath at the beginning (baseline) and end (post-treatment) of each case. Magnesium levels distal to the occlusion will be measured at the first pass of the clot retrieving device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure related serious adverse event</measure>
    <time_frame>intraprocedure, postoperative day 1, 1 month, 3 month</time_frame>
    <description>Periprocedural clinical, radiographic and laboratory data will be collected and analyzed to detect Mg related adverse events. Outcome will be assessed perioperatively and at 24 hours, 30 days (+/- 10 days) and 90 days (+/- 15 days)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Regional Intra-arterial Magnesium 0.75g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional Intra-arterial magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional/ Distal (75/25%) Magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional/ Distal (50/50%) Magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Intra-arterial</description>
    <arm_group_label>Regional Intra-arterial Magnesium 0.75g</arm_group_label>
    <arm_group_label>Regional Intra-arterial magnesium 1.5g</arm_group_label>
    <arm_group_label>Regional/ Distal (75/25%) Magnesium 1.5g</arm_group_label>
    <arm_group_label>Regional/ Distal (50/50%) Magnesium 1.5g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with acute cerebral ischemia due to ICA or MCA occlusion,

          2. Patient's clinical attending physician plans mechanical embolectomy procedure as part
             of routine clinical care.

          3. Age 21-95.

        Exclusion Criteria:

          1. Severe renal impairment with creatinine 3.0 or higher,

          2. Myasthenia gravis,

          3. Second or third degree heart block without a pacemaker in place,

          4. Technical inability to navigate microcatheter to target clot,

          5. Patient already enrolled in another experimental treatment trial. Exclusion criteria
             1-3 are all contraindications to magnesium therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Saver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University California Los Angeles: Ronald Reagan and Santa Monica Hospitals</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California University and LA County Hospitals</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 27, 2016</lastchanged_date>
  <firstreceived_date>December 22, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>William Mack</investigator_full_name>
    <investigator_title>Assistant Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>Magnesium</keyword>
  <keyword>endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
